A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

被引:256
作者
Hoeper, MM [1 ]
Olschewski, H
Ghofrani, HA
Wilkens, H
Winkler, J
Borst, MM
Niedermeyer, J
Fabel, H
Seeger, W
机构
[1] Hannover Med Sch, Dept Pulm Med, D-30623 Hannover, Germany
[2] Univ Giessen, Dept Internal Med, D-6300 Giessen, Germany
[3] Univ Saarland, Dept Pulm Med, D-6650 Homburg, Germany
[4] Univ Leipzig, Dept Internal Med, D-7010 Leipzig, Germany
[5] Heidelberg Univ, Dept Internal Med, D-6900 Heidelberg, Germany
关键词
D O I
10.1016/S0735-1097(99)00494-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE We sought to compare the acute hemodynamic effects of inhaled nitric oxide (NO) and aerosolized iloprost in primary pulmonary hypertension (PPH). BACKGROUND Inhalation of the stable prostacyclin analogue iloprost has recently been described as a novel therapeutic strategy for PPH and may offer an alternative to continuous intravenous infusion of prostacyclin or inhalation of NO. METHODS During right heart catheterization, 35 patients with PPH sequentially inhaled 30 ppm of NO and 14 to 17 mu g of iloprost, and the effects on hemodynamics and blood gases were monitored. RESULTS Both NO and iloprost caused significant increases in cardiac output, mixed-venous oxygen saturation and stroke volume as well as significant decreases in pulmonary artery pressure and pulmonary vascular resistance, whereas only inhaled iloprost significantly increased the arterial Po-2 (p = 0.01). Compared with inhaled NO, aerosolized iloprost was more effective in reducing pulmonary artery pressure (-8.3 +/- 7.5 mm Hg vs. -4.3 +/- 8.8 mm Hg; p = 0.0001) and the pulmonary vascular resistance (-447 +/- 340 dynes.s.cm(-5) vs. -183 +/- 305 dyne.s.cm(-5); p < 0.0001). Furthermore, aerosolized iloprost caused a significantly greater increase of the cardiac output compared with NO (+0.7 +/- 0.6 liter/min vs. +0.3 +/- 0.4 liter/min; p = 0.0002) and had a more pronounced effect on the mixed-venous oxygen saturation (p = 0.003). CONCLUSIONS During acute drug testing, aerosolized iloprost was more potent than inhaled NO as a pulmonary vasodilator in PPH at the doses used in this study. (C) 1999 by the American College of Cardiology.
引用
收藏
页码:176 / 182
页数:7
相关论文
共 27 条
[1]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[2]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415
[3]  
FROSTELL C, 1991, CIRCULATION, V84, P2212
[4]  
HIGENBOTTAM T, 1984, LANCET, V1, P1046
[5]  
Hinderliter AL, 1997, CIRCULATION, V95, P1479
[6]  
Höper MM, 1997, AM J RESP CELL MOL, V17, P748
[7]   Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange [J].
Jolliet, P ;
Bulpa, P ;
Thorens, JB ;
Ritz, M ;
Chevrolet, JC .
THORAX, 1997, 52 (04) :369-372
[8]  
Magnani B, 1996, EUR HEART J, V17, P18
[9]   Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [J].
McLaughlin, VV ;
Genthner, DE ;
Panella, MM ;
Rich, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :273-277
[10]   REBOUND PULMONARY-HYPERTENSION ON WITHDRAWAL FROM INHALED NITRIC-OXIDE [J].
MILLER, OI ;
TANG, SF ;
KEECH, A ;
CELERMAJER, DS .
LANCET, 1995, 346 (8966) :51-52